Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
PENTA Foundation
Anna Turkova; Ellen White; Hilda A Mujuru; Adeodata R Kekitiinwa; Cissy M Kityo; Avy Violari; Abbas Lugemwa; Tim R Cressey; Philippa Musoke; Ebrahim Variava; Mark F Cotton; Moherndran Archary; Thanyawee Puthanakit; Osee Behuhuma; Robin Kobbe; Steven B Welch; Mutsa Bwakura-Dangarembizi; Pauline Amuge; Elizabeth Kaudha; Linda Barlow-Mosha; Shafic Makumbi; Nastassja Ramsagar; Chaiwat Ngampiyaskul; Godfrey Musoro; Lorna Atwine; Afaaf Liberty; Victor Musiime; Dickson Bbuye; Grace M Ahimbisibwe; Suwalai Chalermpantmetagul; Shabinah Ali; Tatiana Sarfati; Ben Wynne; Clare Shakeshaft; Angela Colbers; Nigel Klein; Sarah Bernays; Yacine Saïdi; Alexandra Coelho; Tiziana Grossele; Alexandra Compagnucci; Carlo Giaquinto; Pablo Rojo; Deborah Ford; Diana M Gibb; ODYSSEY Trial Team